ABBVIE Company Profile

✉ Email this page to a colleague

What is the competitive landscape for ABBVIE, and what generic alternatives to ABBVIE drugs are available?

ABBVIE has one hundred and thirty-eight approved drugs.

There are two hundred and twenty-nine US patents protecting ABBVIE drugs.

There are two thousand seven hundred and twenty-six patent family members on ABBVIE drugs in sixty-six countries and three hundred and ninety-three supplementary protection certificates in nineteen countries.

Summary for ABBVIE

International Patents:	2726
US Patents:	229
Tradenames:	124
Ingredients:	99
NDAs:	138
Drug Master File Entries:	1
Patent Litigation for ABBVIE:	See patent lawsuits for ABBVIE

Drugs and US Patents for ABBVIE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333-001	Apr 29, 2015	AP	RX	Yes	Yes	7,754,230	⤷ Try a Trial				⤷ Try a Trial
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-001	Apr 11, 2016		RX	Yes	No	11,590,128	⤷ Try a Trial				⤷ Try a Trial
Abbvie	LUMIGAN	bimatoprost	SOLUTION/DROPS;OPHTHALMIC	022184-001	Aug 31, 2010		RX	Yes	Yes	8,772,338	⤷ Try a Trial	Y			⤷ Try a Trial
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-003	Mar 16, 2022		RX	Yes	Yes	11,773,105	⤷ Try a Trial	Y	Y		⤷ Try a Trial
Abbvie	ZEMPLAR	paricalcitol	CAPSULE;ORAL	021606-001	May 26, 2005	AB	RX	Yes	No		⤷ Try a Trial				⤷ Try a Trial
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-003	Apr 11, 2016		RX	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ABBVIE

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020517-002	May 30, 1997	5,476,663	⤷ Try a Trial
Abbvie	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-003	Jan 14, 2009	6,602,911	⤷ Try a Trial
Abbvie	ACULAR	ketorolac tromethamine	SOLUTION/DROPS;OPHTHALMIC	019700-001	Nov 9, 1992	5,110,493*PED	⤷ Try a Trial
Abbvie	KALETRA	lopinavir; ritonavir	SOLUTION;ORAL	021251-001	Sep 15, 2000	5,484,801*PED	⤷ Try a Trial
Abbvie	ALPHAGAN P	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	021770-001	Aug 19, 2005	6,641,834*PED	⤷ Try a Trial
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020011-001	Oct 22, 1990	5,631,020	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for ABBVIE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Ophthalmic Solution	0.2%/0.5%	➤ Subscribe	2008-11-21
➤ Subscribe	Extended-release Tablets	4 mg/ 240 mg	➤ Subscribe	2007-07-24
➤ Subscribe	Tablets	100 mg	➤ Subscribe	2010-12-21
➤ Subscribe	Ophthalmic Solution	0.03%	➤ Subscribe	2008-12-22
➤ Subscribe	Tablets	1 mg, 2 mg and 4 mg	➤ Subscribe	2004-10-04
➤ Subscribe	Injection	0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials	➤ Subscribe	2008-11-28
➤ Subscribe	Ophthalmic Solution	0.5%	➤ Subscribe	2010-12-07
➤ Subscribe	Delayed-release Capsules	45 mg	➤ Subscribe	2009-09-02
➤ Subscribe	Tablets	12.5 mg, 25 mg, 50 mg, and 100 mg	➤ Subscribe	2013-01-14
➤ Subscribe	Capsules	4 mcg	➤ Subscribe	2008-08-25
➤ Subscribe	Capsules	5 mg	➤ Subscribe	2005-08-17
➤ Subscribe	Extended-release Capsules	20 mg, 40 mg, 80 mg and 120 mg	➤ Subscribe	2017-07-25
➤ Subscribe	Tablets	48 mg	➤ Subscribe	2008-07-01
➤ Subscribe	Gel	10%	➤ Subscribe	2014-06-19
➤ Subscribe	Injection	10 mg/mL (2 mL)	➤ Subscribe	2018-07-13
➤ Subscribe	Extended-release Capsules	28 mg	➤ Subscribe	2013-06-12
➤ Subscribe	Tablets	2.5 mg/200 mg	➤ Subscribe	2006-02-24
➤ Subscribe	Injection	2 mg/mL, 10 mL vial	➤ Subscribe	2009-08-12
➤ Subscribe	Delayed-release Tablets	800 mg	➤ Subscribe	2011-07-13
➤ Subscribe	Extended-release Capsules	7 mg, 14 mg, 21 mg, and 28 mg	➤ Subscribe	2013-06-10
➤ Subscribe	Tablets	10 mg, 20 mg, and 40 mg	➤ Subscribe	2015-01-21
➤ Subscribe	Ophthalmic Solution	0.40%	➤ Subscribe	2005-01-28
➤ Subscribe	Extended-release Tablets	250 mg	➤ Subscribe	2004-05-03
➤ Subscribe	Capsules	21 mg/10 mg	➤ Subscribe	2016-09-23
➤ Subscribe	Opthalmic Solution	0.45%	➤ Subscribe	2011-08-24
➤ Subscribe	Extended-release Tablets	7.5 mg and 15 mg	➤ Subscribe	2008-12-22
➤ Subscribe	Tablets	100 mg/25 mg	➤ Subscribe	2008-12-23
➤ Subscribe	Ophthalmic Solution	0.15%	➤ Subscribe	2006-11-03
➤ Subscribe	Extended-release Tablets	1 mg/240 mg	➤ Subscribe	2008-02-20
➤ Subscribe	Capsules	145 mcg and 290 mcg	➤ Subscribe	2016-08-30
➤ Subscribe	Ophthalmic Solution	0.25%	➤ Subscribe	2014-07-30
➤ Subscribe	Tablets	5 mg/80 mg	➤ Subscribe	2017-06-09
➤ Subscribe	Capsules	100 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Delayed-release Capsules	400 mg	➤ Subscribe	2014-06-17
➤ Subscribe	Ophthalmic Solution	0.01%	➤ Subscribe	2011-04-05
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2007-10-16
➤ Subscribe	Capsules	1 mcg and 2 mcg	➤ Subscribe	2008-10-14
➤ Subscribe	Topical Solution	0.03%	➤ Subscribe	2010-05-03
➤ Subscribe	Delayed-release Capsules	135 mg	➤ Subscribe	2009-09-01
➤ Subscribe	Tablets	400 mg and 600 mg	➤ Subscribe	2010-05-10
➤ Subscribe	Gel	7.5%	➤ Subscribe	2017-02-13
➤ Subscribe	Capsules	10 mg and 20 mg	➤ Subscribe	2005-03-30
➤ Subscribe	Extended-release Capsules	7 mg, 14 mg, 21 mg, and 28 mg	➤ Subscribe	2013-08-16
➤ Subscribe	Tablets	145 mg	➤ Subscribe	2007-10-19
➤ Subscribe	Injection	2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial	➤ Subscribe	2009-08-04
➤ Subscribe	Suppository	1000 mg	➤ Subscribe	2013-05-24
➤ Subscribe	Extended-release Capsules	7 mg, 14 mg, 21 mg	➤ Subscribe	2013-06-17
➤ Subscribe	Tablets	5 mg/200 mg	➤ Subscribe	2005-05-27
➤ Subscribe	Injection	400 mg/vial and 600 mg/vial	➤ Subscribe	2014-10-29
➤ Subscribe	Extended-release Tablet	500 mg	➤ Subscribe	2010-12-06
➤ Subscribe	Capsules	14 mg/10 mg and 28 mg/10 mg	➤ Subscribe	2015-05-18
➤ Subscribe	Opthalmic Solution	0.45%	➤ Subscribe	2011-08-23
➤ Subscribe	Extended-release Tablets	500 mg	➤ Subscribe	2005-02-08
➤ Subscribe	Capsules	7 mg/10 mg	➤ Subscribe	2016-09-26
➤ Subscribe	Ophthalmic Solution	0.10%	➤ Subscribe	2006-12-20
➤ Subscribe	Extended-release Tablets	2 mg/180 mg and 2 mg/240 mg	➤ Subscribe	2007-11-09
➤ Subscribe	Oral Solution	80 mg/20 mg per mL	➤ Subscribe	2014-06-19

International Patents for ABBVIE Drugs

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Japan	2013535505	⤷ Try a Trial
South Korea	20160098476	⤷ Try a Trial
Australia	2014368818	⤷ Try a Trial
Hong Kong	1199816	⤷ Try a Trial
Nicaragua	201300043	⤷ Try a Trial
Dominican Republic	P2011000367	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for ABBVIE Drugs

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1856135	2020/017	Ireland	⤷ Try a Trial	PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTRATION NO/DATE: EU/1/19/1405 20200113
2340029	599	Finland	⤷ Try a Trial
1453521	300814	Netherlands	⤷ Try a Trial	PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
2692346	PA2017033	Lithuania	⤷ Try a Trial	PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726
2368890	92668	Luxembourg	⤷ Try a Trial	PRODUCT NAME: OMBITASVIR, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX R); FIRST REGISTRATION DATE: 20150119
2340029	304 50009-2015	Slovakia	⤷ Try a Trial	PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: EU/1/14/982/001 20150119
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Summary for ABBVIE

Paragraph IV (Patent) Challenges for ABBVIE drugs

Similar Applicant Names

Make Better Decisions: Try a trial or see plans & pricing